Furthermore, 9 out of 38 subjects (23.7%) investigated for gene mutations associated with myelodysplastic syndromes or other onco-hematological disorders were found to carry such mutations (DNMT3A in 7 cases, EZH2 in 1 case, and TP53 in 1 case). This evidence concerns the gene EZH2 and myelodysplastic syndrome.